# A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation

Source: https://onco.cc/trials/nct07259590/  
OnCo record `nct07259590` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of GFH375, Cetuximab, Paclitaxel / nab-paclitaxel in colorectal cancer, run by Genfleet Therapeutics (Shanghai) Inc., now recruiting.

## Summary

A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation is a phase 1/2 interventional study registered as NCT07259590 by Genfleet Therapeutics (Shanghai) Inc., with 126 participants planned, started 2025-10-21 and due to reach its primary completion in 2027-07. Interventions recorded: GFH375, GFH375. Conditions listed: Advanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07259590
- Phase: 1/2
- Setting: A Multicenter, Open-Label, Phase Ib/II Clinical Study to Explore the Efficacy, Pharmacokinetics and Safety/Tolerability of GFH375 in Combination With Cetuximab or Chemotherapy in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutation
- Sponsor: Genfleet Therapeutics (Shanghai) Inc.
- Enrolled: 126

## Sources

- ClinicalTrials.gov NCT07259590: https://clinicaltrials.gov/study/NCT07259590

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [GFH375](https://onco.cc/drugs/gfh375/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)

---
JSON: https://onco.cc/api/v1/entities/nct07259590.json